Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Account Payables (2016 - 2021)

Guided Therapeutics' Change in Account Payables history spans 11 years, with the latest figure at -$84000.0 for Q2 2021.

  • For Q2 2021, Change in Account Payables fell 197.67% year-over-year to -$84000.0; the TTM value through Jun 2021 reached -$446000.0, down 4560.0%, while the annual FY2020 figure was -$372000.0, 1960.0% down from the prior year.
  • Change in Account Payables for Q2 2021 was -$84000.0 at Guided Therapeutics, down from $29000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $148000.0 in Q1 2017 and bottomed at -$208000.0 in Q3 2020.
  • The 5-year median for Change in Account Payables is $20500.0 (2018), against an average of $388.89.
  • The largest annual shift saw Change in Account Payables surged 353.33% in 2019 before it crashed 730.3% in 2020.
  • A 5-year view of Change in Account Payables shows it stood at $54000.0 in 2017, then dropped by 22.22% to $42000.0 in 2018, then tumbled by 200.0% to -$42000.0 in 2019, then crashed by 335.71% to -$183000.0 in 2020, then surged by 54.1% to -$84000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTHP's Change in Account Payables are -$84000.0 (Q2 2021), $29000.0 (Q1 2021), and -$183000.0 (Q4 2020).